(MGN) is a slowly progressive disease of the affecting mostly patients between ages of 30 and 50 years, usually Caucasian. It is the second most common cause of nephrotic syndrome in adults, withThe incidence of minimal change disease is higher in children with a reported incidence of 2 per 100,000 per year in children and higher rates in Arabian and Asian children".
Although the exact mechanisms causing pMN are still under investigation, different studies show a strong relationship between antibody levels to podocytic and disease activity. Since the discovery of anti-PLA2R1 by Beck et al. in 2009, there has been strong evidence that they are a key player in the pathogenesis.
The incidence of is about 3 new cases per 100,000 each year in adults.In adults, diabetes mellitus is the most common secondary cause, and focal segmental glomerulosclerosis and membranous nephropathy are the most common primary causes. Minimal change disease accounts for 10%-25% of cases of nephrotic syndrome in adults.
Nephrotic syndrome is a relatively rare but important manifestation of kidney disease. Using the algorithm for predicting outcome described, we can rationally assign patients to conservative, nonimmunosuppressive therapy or to therapy according to their risk for renal disease progression.
Major research on disease:
Outcomes research in glomerulonephritis. It is present in every patient with membranous nephropathy and the process affects all glomeruli in both kidneys. Development of proprietary assays for the identified biomarkers and assess their diagnostic and predictive values in large cohorts.